Apple Inc. (AAPL) v. Samsung: ITC to Review Ruling

Apple Inc. (NASDAQ:AAPL) and Samsung Electronics Co. Ltd., have been involved in several legal discussions, shall we say, in several countries around the world regarding infringement or non-infringement of various patents. One in particular, which was decided by an administrative law judge on behalf of the U.S. International Trade Commission, is now under an appeal process of sorts – but one not brought up by either party.

The full ITC decided this week that it wanted to review the September ruling by the presiding administrative law judge who determined that Apple Inc. (NASDAQ:AAPL) did not infringe on four Samsung patents, with three of the patents being ruled valid and the fourth invalid with none of them infringed upon.

Apple Inc. (AAPL)

What is at issue in the review, says the ITC, is the issue of licensing standards-essential patents to accused infringers, how the FRAND process and design-around process works and whether a there should be an import ban on devices when there is a licensing agreement being negotiated or implemented and determining the amount of harm that could result. Apple Inc. (NASDAQ:AAPL) has been showing little if any interest in negotiating licensing, and instead has been insisting that it has the patents and that Samsung is the one doing the infringing, but perhaps an ITC review can help establish a framework for these companies to potentially reach an agreement.

The ITC has indicated that it wants all of the important information about standards-essential patents  from both parties in this case, government agencies (which includes the Federal Trade Commission) and the Office of Unfair Import Investigations, among others, as well as possible remedies for cases like Apple Inc. (NASDAQ:AAPL) v. Samsung, by Monday, Dec. 3. As Apple is the most popular stock holding among hedge funds, what do you think would be the impact or effect of this investigation on Apple as a company, on its stock and on the holdings of investors like billionaire Julian Robertson of Tiger Management?

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!